eConsent in Clinical Trials: How It Works and FDA Rules

It's Tuesday morning at a study site in Melbourne. Nadia, the research coordinator, is 40 minutes into a consent visit with a newly enrolled participant. Two printed copies of a 22 page consent form sit on the desk. The participant has already initialled eight pages and has six more to go.

Somewhere in the middle is the text she'll need to understand again in 12 weeks, when the protocol amendment lands. Her signature is legal. Whether she'll remember what she agreed to is another question.

Paper informed consent still runs most clinical trials today. It's legal, familiar, and sponsors know how to audit it. It's also slow, error prone, hard to update, and the participant's comprehension is rarely measured. Electronic informed consent, usually shortened to eConsent, was built to fix that first visit. Done well, it improves comprehension, cuts site time, gives a versioned audit trail, and quietly sets the tone for everything after.

This guide to eConsent in clinical trials covers what the acronym means, how electronic informed consent actually works end to end, how it compares to paper, what the FDA, 21 CFR Part 11, ICH, and international regulators expect, and what to look for when choosing eConsent software. At the end, three real trials show eConsent holding up at scale, including a 6,000 participant study across five countries.

What is eConsent in clinical trials?

eConsent is the digital process of obtaining informed consent from a clinical trial participant. It replaces the paper informed consent form (ICF) with interactive content on a smartphone, tablet, or web browser. Participants read the trial information, watch videos, answer comprehension checks, ask questions, and sign electronically. The platform holds the versioned document, the audit trail, and the signed record.

The terms eConsent, electronic informed consent (eIC), digital consent form, and electronic consent forms all point to the same thing. FDA guidance uses "electronic informed consent." Most vendors and sponsors say "eConsent." In clinical research contexts, they're interchangeable.

WeGuide's eConsent solution sits inside the same platform as our digital form builder, so research teams design consent, screening, and ongoing assessments in one place. Want to see a working flow before reading further? Book a 15 minute walkthrough with our team.

How does eConsent in clinical trials work?

eConsent isn't a PDF on a tablet. At its best, it's a structured digital experience designed around comprehension, regulatory alignment, and easy reconsent when protocols change.

The participant experience

The participant receives an invite, a QR code at a site, or a link in a patient portal. They open the content on their own device or on a provisioned tablet in the clinic. The consent form is broken into short sections.

Each section can include plain language explanations, short videos, diagrams, and glossary terms. Comprehension checks, often a few targeted questions, confirm the participant understood the key points. At the end, they sign electronically.

Where the content is unclear, they ask an investigator or coordinator by phone, video call, or in person. The content also works in the participant's preferred language. On WeGuide, multilingual consent is configured in the same flow, so an Arabic speaker and an English speaker complete the same trial protocol in their own language.

The site and investigator workflow

A trained investigator still leads the consent conversation. The digital form gives the investigator a structured script, tracks which sections the participant has reviewed, flags any comprehension questions that were missed, and records the discussion. The investigator countersigns the document. The site receives a complete, time stamped ICF without scanning, filing, or courier.

The audit trail and document control

Behind the scenes, every action is logged. Which ICF version was presented, who signed, when each section was opened, how long the participant spent on it, and any failed comprehension checks all sit in a version controlled audit trail.

When the IRB approves a protocol amendment, the new ICF version is deployed and participants are prompted to reconsent. The old and new versions stay linked in the record, which matters a lot at inspection time.

eConsent vs paper consent: the key differences

Paper consent works. That's not in question. The useful question is what eConsent changes across a trial's life. The table below is the short version.

None of this means eConsent is automatic. It still needs good ICF content, IRB review, site training, and honest design. What it does give you is a cleaner starting line and a real trail when someone asks how version 3.2 was deployed on 14 May.

Benefits of eConsent

When the design is right, eConsent improves the things sponsors actually care about: comprehension, enrolment, data quality, and site burden.

1. Better participant comprehension. Short sections, videos, and comprehension checks help more participants understand what they're agreeing to, particularly with complex protocols. A 2026 peer reviewed report across nearly 12,000 participants found that structured electronic consent supported higher comprehension and completion rates than paper alone (Appelbe et al., 2026).
2. Wider enrolment reach. Remote and hybrid consent opens the trial to participants who can't easily travel to a site, which helps with both enrolment speed and representation.
3. Cleaner audit trail and version control. Versioned documents, time stamps, and automatic logging cut down the back and forth at monitoring visits and inspections.
4. Lower consent related protocol deviations. Missing initials, unsigned pages, and expired ICF versions are among the most common and most avoidable deviation types. Digital validation prevents most of them at source.
5. Easier reconsent. When a protocol amendment lands, new consent can be pushed to every active participant in days, not months.
6. Multilingual support from day one. Translating and deploying a new language version is a configuration task, not a printing run.
7. Less first visit burden on sites. Scanning, filing, and couriering paper ICFs goes away. Sites spend more of the first visit on the participant and less on admin.
8. Faster multi-site activation. A single approved ICF version rolls out to every site and device at once.

Most research teams only need two or three of these benefits to justify the switch. Many realise the rest once they're running.

eConsent FDA requirements and regulatory compliance

eConsent is compatible with every major clinical trial regulation. It isn't a workaround or a grey zone. The regulators have been clear for a decade that electronic systems are acceptable when they meet the same standards as paper.

FDA guidance on electronic informed consent

The FDA's 2016 guidance, Use of Electronic Informed Consent in Clinical Investigations: Questions and Answers, is the primary reference. It confirms that eConsent is acceptable, outlines the expected content and format, and covers identity verification, questions from participants, and IRB responsibilities. The guidance is jointly issued with HHS and applies to both FDA regulated and Common Rule research.

21 CFR Part 11

21 CFR Part 11 covers electronic records and electronic signatures. Any eConsent platform used for FDA regulated trials must meet Part 11 requirements. That includes a validated system, secure access controls, trustworthy audit trails, and electronic signatures that are legally equivalent to handwritten ones.

21 CFR Part 50 and the Common Rule

Informed consent itself is governed by 21 CFR Part 50 for FDA regulated research and by 45 CFR 46 (the Common Rule) for federally funded research. The content requirements, the right to withdraw, the investigator's role, and IRB oversight all apply identically whether the ICF is on paper or on a screen. eConsent doesn't change what the document has to say. It changes how it's presented and recorded.

ICH E6 good clinical practice

ICH E6(R2), with E6(R3) now finalised, sets the good clinical practice baseline globally. It acknowledges electronic systems explicitly and expects the same data integrity (attributable, legible, contemporaneous, original, accurate, ALCOA) standards for eConsent as for any other trial record.

HIPAA, GDPR, and international context

Protecting participant data is a separate requirement layered on top. In the US, HIPAA applies when protected health information moves through the system. In the EU and UK, GDPR applies. In Australia, the Privacy Act and TGA expectations apply, with NHMRC guidance on the conduct of research.

An eConsent platform needs to be configurable to each of these. WeGuide is TGA Class I certified medical device software, and our platform supports these privacy and good clinical practice standards. That's not the same as saying it guarantees compliance for any specific trial, which is a conversation with your regulatory adviser and your IRB or ethics committee.

Regulatory note: eConsent is permitted by the FDA, EMA, TGA, and MHRA, but country and state level rules vary. Always confirm with your IRB or ethics committee before rolling out electronic consent in a new jurisdiction.

Can eConsent be used in decentralised clinical trials?

Yes. eConsent is one of the building blocks that makes decentralised clinical trials (DCTs) possible. Remote participants verify their identity digitally, review the ICF on their own device, talk to the investigator over telehealth, ask questions in real time, and sign electronically. The same audit trail captures every step.

Most DCTs are actually hybrid. Some visits are remote, others happen at a site. The consent itself can be hybrid too, opened at home, finished in the clinic, or the other way around. Good eConsent software handles both without forcing a re-entry.

What to look for in eConsent software

The best way to evaluate eConsent software is to run a real ICF through a demo. Short of that, the checklist below covers what matters in practice.

• Validated templates and form builder. Can you build and version your ICF without custom code?
• Protocol amendment workflow. How easy is reconsent when the protocol changes mid study?
• Multilingual support. How are translations managed, reviewed, and deployed?
• Comprehension features. Videos, quizzes, glossary terms, conditional logic, not just scrolling text.
• Identity verification. What options exist for remote ID checks?
• Electronic signatures. Do the signatures meet 21 CFR Part 11 and eIDAS equivalents?
• Ready for IRB review. Can you export a full, time stamped audit trail per participant?
• Integration with EDC and CTMS. Does consent status flow to your study database?
• Analytics across sites. Can you monitor consent progress and drop off in real time from a single analytics dashboard?
• Partnership, not vendor. Will the platform team help you design the ICF, or hand over a tool and walk away?

If you want the full clinical trial solutions picture rather than eConsent alone, we put this checklist and a live demo together in one session.

Implementing eConsent in your next trial

Most teams run into the same four steps when they roll out eConsent for the first time. In order:

ICF design with your IRB and research team

Work backwards from the IRB's expectations. Draft the ICF content in plain language, decide where comprehension checks sit, and agree which sections need videos or diagrams. Sponsor, IRB, investigator, and platform team all see the draft before build.

Build, validate, and translate

Configure the ICF in the platform, add conditional logic and comprehension checks, and validate against test cases. Translations happen next, ideally through a certified translator who understands the target community. CALD participants are poorly served by machine translation alone.

Site and participant onboarding

Train sites in the new flow. Most site staff find eConsent easier than paper within a single training session, but they need walkthroughs of identity verification, reconsent, and where to find support. Participant facing instructions live inside the app so there's no new document to hand out.

Monitor, reconsent, and amend safely

Once enrolment starts, monitor consent progress, drop off, and comprehension check patterns. When the IRB approves an amendment, push a new ICF version and prompt reconsent for active participants. The audit trail makes this routine, not a fire drill.

eConsent in the real world: evidence from live studies

The best argument for eConsent is watching it work under pressure. Three WeGuide studies put different parts of the approach through its paces.

The BRACE Trial is a 6,000 participant randomised controlled study of the BCG vaccine's broader immune effects, led by the Murdoch Children's Research Institute and run across five countries during COVID-19. Site visits were restricted and in some countries impossible. The trial launched within six weeks using remote onboarding, electronic consent, and digital follow up. Participant adherence held above 90%. Read the BRACE Trial case study.

The INHERIT study is a COVID-19 research programme designed for culturally and linguistically diverse (CALD) communities in Australia. Paper consent in English would have excluded most of the population the study needed to reach. WeGuide's platform supported consent and ongoing data collection in multiple languages, with the content adapted rather than machine translated. See how INHERIT engaged CALD communities.

The GenV population study recruits newborn families across Victoria. More than 100,000 families are enrolled. At that scale, paper consent and paper data capture aren't options. Digital consent with accessible, inclusive content is what makes ongoing participation practical for families. Read the GenV story.

Different trial types, different participant groups, same point. When the consent moment is designed well, it's the start of engagement, not the first piece of friction.

The future of eConsent

Three shifts will shape eConsent over the next few years. Decentralised and hybrid trial designs will keep growing, which means remote consent tooling has to match the sophistication of on-site workflows. AI supported comprehension checks will move from novelty to default, not making medical decisions, just helping test whether a participant understood the study. And wearable linked enrolment, where a participant's device data helps screen eligibility before consent even begins, will become more common in observational and DCT settings.

None of that replaces the central point. A trial's relationship with its participant starts at consent. Everything downstream, adherence, retention, data quality, the eventual endpoint, depends on whether that first visit worked.

Key takeaways

• eConsent in clinical trials is the digital process of obtaining informed consent, covering ICF presentation, comprehension checks, electronic signature, and the audit trail.
• It's explicitly permitted by FDA guidance, 21 CFR Part 11, 21 CFR Part 50, the Common Rule, ICH E6, and major international regulators.
• The benefits that matter most in practice are better comprehension, wider enrolment, cleaner audit trails, easier reconsent, and less site burden.
• eConsent is a building block of decentralised clinical trials and hybrid designs, but it works just as well for traditional site based studies.
• Real trials at scale, including BRACE (6,000 participants, 5 countries, 90% adherence), INHERIT (CALD communities), and GenV (100,000+ families), show eConsent holding up well beyond the pilot stage.

If you're planning an eConsent rollout, the next step is a walkthrough against your actual protocol. Book a demo of WeGuide's eConsent platform and we'll show you how the ICF, comprehension checks, translations, reconsent, and audit trail work together in one place. Already using eCOA in your trial? See our companion piece on the key differences between eCOA and ePRO.

‍